



Curriculum Vitae

Personal information **Manuel Campos Toimil**

Work experience

1. Employer: University of Santiago de Compostela
 - Start date: 112010
 - End date:
 - Position: Profesor Titular de Universidad
 - Activities:
 - Country: Spain
2. Employer: University of Cambridge
 - Start date: 061999
 - End date: 022001
 - Position: Research Associate
 - Activities:
 - Country: United Kingdom
3. Employer: University of Santiago de Compostela
 - Start date: 102003
 - End date: 092008
 - Position: 'Ramón y Cajal' Researcher
 - Activities:
 - Country: Spain

Education and training

1. Subject: University of Santiago de Compostela
 - Start date:
 - End date: 071995
 - Qualification: PhD Pharmacy
 - Organisation: Pharmacology
 - Country: Spain

Additional information

Publications

JCR INDEXED MANUSCRIPTS 1. Matos MJ, Uriarte E, Seoane N, Picos A, Gil_Longo J, Campos_Toimil M. Synthesis and vasorelaxant activity of nitrate_coumarin derivatives. ChemMedChem (In press). 2. Carvalho GR, Braz DS, Gonçalves TCO, Aires R, Côco LZ, Guidoni M, Fronza M, Endringer DC, de Souza Junior AD, Campos_Toimil M, Nogueira BV, Vasquez EC, Campagnaro BC, Pereira TMC. Development and evaluation of Virola oleifera formulation for cutaneous wound healing. Antioxidants (Basel) 2021, 11(9), 1647. 3. Bandín_Vilar E, García_Quintanilla L, Castro_Balado A, Zarra_Ferro I, Gonzalez_Barcia M, Campos_Toimil M, Mangas Sanjuan V, Mondelo Garcia C, Fernández_Ferreiro A. A review of population pharmacokinetics analyses of linezolid. Clinical Pharmacokinetics 2022. 4. Pereira TMC, Carvalho GR, Luaces_Regueira M, Bugallo_Casal A, Iglesias_Mejuto A, Nugteren L, Schmidt M, Viña D, Vasquez EC, Campos_Toimil M. Nanomolar resveratrol reduces early alterations of pancreatitis and pancreatic cancer in pancreatic acinar cells. Phytomedicine Plus, 2022, 2: 100301. 5. Queiroz SAL, Ton AMM, Pereira TMC, Campagnaro BP, Martinelli L, Picos A, Campos_Toimil M*, Vasquez EC. The gut microbiota_brain axis: a new frontier on neuropsychiatric disorders. Frontiers in Psychiatry 2022, 13: 872594. 6. Aragón_Herrera A, Otero_Santiago M, Anido_Varela L, Moraña_Fernández S, Campos_Toimil M, García_Caballero T, Barral L, Tarazón E, Roselló_Lletí E, Portolés M, Gualillo O, Moscoso I, Lage R, González_Juanatey JR, Feijóo_Bandín S, Lago F. The treatment with the SGLT2 inhibitor empagliflozin modifies the hepatic metabolome of male Zucker diabetic fatty rats towards a protective profile. Frontiers Pharmacol 2022, 13: 827033. 7. Pereira TMC, Côco LZ, Ton AMM, Meyrelles SS, Campos_Toimil M, Campagnaro BP, Vasquez EC. The emerging scenario of gut_brain axis: The therapeutic actions of the new actor kefir against neurodegenerative diseases. Antioxidants (Basel) 2021, 10(11). 1845. 8. Viña D, Seoane N, Vasquez EC, Campos_Toimil M. cAMP compartmentalization in cerebrovascular endothelial cells: new therapeutic opportunities in Alzheimer's disease. Cells 2021, 10(8): 1951. 9. Hashem_Dabaghian F, Ghods R, Shojaii A, Abdi L, Campos_Toimil M, Yousefsani B.S. Rhus coriaria L., a new candidate for controlling metabolic syndrome: A systematic review. J Pharm Pharmacol 2021, rgab120. 10. Rubiolo JA, Lence E, González_Bello C, Roel M, Gil_Longo J, Campos_Toimil M, TERNON E, Thomas OP, González_Cantalapiedra A, López_Alonso H, Vieytes MR, Botana LM. Crambesin C1 acts as a possible substrate of iNOS and eNOS increasing nitric oxide production and inducing in vivo hypotensive effect. Frontiers Pharmacol 2021., 12: 694639. 11. Francisco V, Ruiz_Fernández C, González_Rodríguez M, Cordero_Barreal A, Pino J, Viñuela JE, Lago F, Conde J, Gómez R, Carvalho GR, Pereira TMC, Campos_Toimil M, Gualillo O. Evaluation of Virola oleifera activity in musculoskeletal pathologies: inhibition of human multiple myeloma cells proliferation and combination therapy with dexamethasone or bortezomib. J Ethnopharmacol 2021, 272: 113932. 12. Giraldez_Montero JM, Gonzalez_Lopez J, Campos_Toimil M, Lamas_Díaz MJ. Therapeutic drug monitoring of anti_tumour necrosis factor_α agents in inflammatory bowel disease: Limits and improvements. Br J Clin Pharmacol 2021, 87(5): 2216-2227. 13. González_Rodríguez M, Ruiz_Fernández C, Francisco V, Eldjoudi DA, Farrag_AbdElHafez YR, Cordero_Barreal A, Pino J, Lago F, Campos_Toimil M, Rocha Carvalho GR, Melo Costa Pereira T, Gualillo O. Pharmacological extracts and molecules from Virola species: traditional uses, phytochemistry and biological activity. Molecules 2021, 26: 792. 14. Monteiro BL, Dias AT, Wanderkoke SC, Yokota R, Casarini DE, Leal MAS, Nogueira BV, Meyrelles SS, Campos_Toimil M, Campagnaro BP, Campos RR, Pereira TMC, Vasquez EC. Protective effects of kefir in the angiotensin II dependent hypertension. J Funct Foods 2020, 75: 104260. 15. Blanco_Dorado S, Belles_Medall MD, Pascual_Marmaneu O, Campos_Toimil M, Otero_Espinar FJ, Rodríguez_Riego R, Rodríguez_Jato MT, Zarra_Ferro I, Lamas MJ, Fernández_Ferreiro A. Therapeutic drug monitoring of voriconazole: validation of a high performance liquid chromatography method and comparison with an ARK immunoassay. Eur J Hosp Pharm 2020, 0: 1_6. 16. Blanco_Dorado S, Maroñas Amigo O, Latorre_Pellicer A, Rodríguez_Jato MT, López_Vizcaíno A, Gómez_Márquez A, Bardán_García B, Belles_Medall D, Barbeito_Castiñeiras G, Pérez_Del Molino

Alzueta AF, Gil_Longo J, Orallo F. Effects of hydralazine on contractile responses to α_1 and α_2 adrenoceptor agonists in isolated rat aorta. *Gen Pharmacol* 1994, 25(1): 165_172. 60. Orallo F, Alzueta AF, Loza MI, Vivas N, Badía A, Campos M, Honrubia MA., Cadavid MI. Study of the mechanism of the relaxant action of (+)_glucine in rat vas deferens. *Br J Pharmacol* 1993, 110(3): 943_948. 61. Orallo F, Fontenla JA, Loza MI, Campos M, Calleja JM. Effect of urethane on hydralazine-induced tachycardia in rats. *Gen Pharmacol* 1992, 23(6):1143_1147. 62. Gil_Longo J, Orallo F, Verde I, Campos M, Calleja JM. Role of the endothelial system in BAY K 8644 enantiomer and nifedipine vasomodulator action in rat aorta. *Eur J Pharmacol* 1992, 221(1): 1_8. 63. Orallo F, Verde I, Loza MI, Alzueta AF, Campos M, Freire_Garabal M. Effects of platelet activating factor on contractions and 45Ca influx induced by noradrenaline and potassium in rat rubbed and intact aorta. Comparison with its hypotensive effect in anaesthetized normotensive rats. *J Pharm Pharmacol* 1992, 44(4): 344_348. INTERNATIONAL BOOK CHAPTERS 1. Elíes J, Yáñez M, Pereira TMC, Gil_Longo J, MacDougall DA, Campos_Toimil M. An update to calcium binding proteins. En: *Calcium Signaling*, Second Edition. Vol.1 (ISBN: 978_3_030_12457_1). Islam, S., ed. Springer Dordrecht, Heidelberg, Nueva York, Londres, pp: 183_213. (Adv Exp Med Biol 2020, 1131: 183_213. Índice de Impacto JCR: 2.450, Q2). 2. Yáñez M, Gil_Longo J, Campos_Toimil M. Calcium binding proteins. En: *Calcium Signaling* (ISBN: 978_94_007_2888_2). Islam S, ed. Springer Dordrecht, Heidelberg, Nueva York, Londres, 2012, pp: 461_482. (Adv Exp Med Biol. 2012, 740: 461_82. JCR: 1,825, Q2). 3. Campos_Toimil M, Elíes J, Orallo F. Cardiovascular effects of trans_ and cis_ resveratrol. En: *Recent Progress in Medicinal Plants* Vol. 21: *Phytopharmacology and Therapeutic Values* III. ISBN: 1_9336991_1_6. Singh VK, Govil JN, eds. Studium Press LLC, USA, 2008, pp: 263_294. NON_JCR INDEXED MANUSCRITPS 1. Montáns_García R, Gómez_Besteiro MI, Campos_Toimil M, Balboa_Barreiro V. Listado de medicamentos a evitar en atención primaria y su aplicación en pacientes polimedicados. *Galicía Clínica* 2021. In press. 2. Affonso HO, Andreão FL, Porto ML, Meyrelles SS, Vasquez EC, Baldo MP, Campos_Toimil M, Campagnaro BP, Pereira TMC. Nonconventional and conventional biomarkers evaluated in gold medalists beach volleyball players during the 2015 and 2016 seasons (pre_olympic and olympic years). *J Phys Edu Sport (JPES)* 2018, 18(3): 1779_1784. 3. Vasquez EC, Meyrelles SS, Gava AL, Campagnaro BP, Gil_Longo J, Campos_Toimil M, Pereira TMC. Beneficial effects of the synbiotic kefir on the neural control of cardiovascular function. *J Food Microbiol* 2018, 2(S1): 25_33. 4. Luaces_Regueira M, Pereira TMC, Campos_Toimil M. New insights on the effects of prebiotics, probiotics and synbiotics in the gastrointestinal diseases and cancer. *J Food Microbiol* 2018, 2(S1): 19_22. 5. Campos_Toimil M, Salgado F. El genoma, patrimonio de la humanidad. *Eureka!* (supl. científico Diario de Pontevedra) 21/11/2001: p3. 6. Campos_Toimil M. A incidencia das alerxias. *Eureka!* (supl. científico Diario de Pontevedra) 31/10/2001: p6. 7. Campos_Toimil M. O uso do cannabis con fins terapéuticos. *Eureka!* (supl. científico Diario de Pontevedra) 05/06/2001: p9. 8. Campos_Toimil M. Chimpancés e humanos: onde está a diferenca? *Eureka!* (supl. científico Diario de Pontevedra) 09/05/2001: p36. 9. Campos_Toimil M, Lugnier C, Takeda K. Inhibition of agonist_induced rises in internal calcium in human endothelial cells by Ginkgo biloba extract (EGb 761) and rolipram. *Rev Fed Argent Cardiol* 2000, 29(3): 361_365. 10. Campos_Toimil, M. O extracto de Ginkgo biloba, un remedio milenario na medicina do século XXI. *Rev Gal Ensino* 1999, 25: 181_190. 11. Campos_Toimil, M. Aplicaciones terapéuticas del Egb 761, extracto de Ginkgo biloba. *OFFARM* 1998, 17(6): 74_80. 12. Campos_Toimil M. Amlodipino: un nuevo antagonista del calcio con acción prolongada de comienzo gradual. *OFFARM* 1996, 15(11): 61_66. 13. Campos M, Orallo F. La hidralazina: 50 años de investigación farmacológica II. *Rev OFIL* 1996, 6(3): 189_198. 14. Campos M, Orallo F. La hidralazina: 50 años de investigación farmacológica I. *Rev OFIL* 1996, 6(2): 115_124. 15. Campos M, Loza I, Fernández_Alzueta A, Orallo F, Longo J, Calleja JM. Actividad antiserotonínica de la glucina en aorta sin endotelio y en conducto deferente aislados de rata. *Ars Pharm* 1992, 33(1_4): 578_583. 16. Loza I, Honrubia M, Fernández_Alzueta A, Campos M, Orallo F, Cadavid M, Gato A. Estudio de la actividad farmacológica de la glucina en fundus de estómago aislado de rata. *Ars Pharm* 1992, 33(1_4): 584_589. 17. Verde I, Orallo F, Gil_Longo J, Campos M. Efectos del endotelio sobre las contracciones inducidas por noradrenalina y K+ en las aortas de rata genéticamente hipertensa y rata normotensa. *Ars Pharm* 1992, 33(1_4): 641_646. 18. Fernandez_Alzueta A, Loza I, Orallo F, Campos M, Cadavid M. Acciones farmacológicas de la glucina y la nantenina en aurículas aisladas de rata. *Ars Pharm* 1992, 33(1_4): 567_571. 19. Verde I, Loza M, Gil_Longo J, Campos M, Orallo F, Calleja JM. Modulación por el endotelio de las contracciones inducidas por distintos agonistas alfa_adrenérgicos en la aorta de rata. *Pharm. Med.* 1990, 19: 459_464.

Projects

1. Stimulation of NO/cGMP and cAMP pathways in the blood_brain barrier: a new therapeutic strategy in Alzheimer's disease (CYCLICBBB). Agencia Estatal de Investigación. Ministerio de Ciencia e Innovación (Spain). Reference: PID2020_119178GB_I00. 01/09/2021_31/08/2024. 84.700,00 €. 2. New biotechnological procedures in the treatment of chronic cardiovascular diseases and neurodegenerative cerebrovascular diseases. Support Program for Nuclei of Excellence (PRONEX), Fundación de Amparo a la Investigación e Innovación de Espírito Santo (FAPES), Brazil. Reference: CNPq/FAPES Nº 24/2018. 01/02/2019_31_01/2022. 373.460,00 BRL (~79.982,00 €). 3. Expertos universitarios para la prestación de servicios técnicos en el proceso de certificación en proyectos de I+D+I. DNV GL Business Assurance España SLU. Reference: 2015_CE104. 26/06/2015_25/06/2021. 12.350,00 €. 4. General research grants. Mode 1. GI_1683. Universidad de Santiago de Compostela. Reference: 2018PU068. 12/06/2018_31/12/2018. 5.000,00 €. 5. Interrelation between Ca2+ and cAMP signaling pathways in human endothelial cells cultured under static and flow conditions. Physiological implications. Subdirección General de Proyectos de Investigación. Ministerio de Ciencia e Innovación. Reference: SAF2010_22051. 01/01/2011_31/12/2011. 24.200,00 €. 6. Interaction between intracellular levels of cyclic AMP and Ca2+ in vascular cells. Implication in the regulation of vascular contractility. Dirección Xeral de I+D. Xunta de Galicia. Reference: INCITE08PXIB203092PR. 31/10/2008_31/10/2011. 78.970,00 €. 7. Intracellular signaling studies. Mechanisms of interaction between cyclic AMP and calcium in vascular cells. Ministerio de Ciencia y Tecnología (Spain). Reference: RYC2002_10. 01/10/2003_30/09/2008. 6000,00 €. 8. Consolidation 2020 CPG GI_1862 Physiology and Pharmacology of Chronic Diseases. Consellería de Cultura, Educación e Universidade, Xunta de Galicia. 01/01/2020_31/12/2022. 90.000,00 €. 9. Evaluation of the intestinal microbiome of newborns of mothers hospitalized for hypertensive states. Ministerio de la Salud. Gobierno de Brasil. 19.000,00 US\$ (~17207,35 €). 10. Consolidation and structuring 2017. Redes_REGID Galician Network for Research and Development of Medicines. Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria. Ref.ED431D 2017/16. 01/01/2017_31/12/2019. 120.000,00 €. 11. Search for new drugs against pancreatitis. Crowdfunding platform 'Precipita'. Fundación Española para la Ciencia y la Tecnología (FECYT). Reference: 2016_CP109. 2016_2017. 23/09/2016_31/12/2017. 5.974,31 €. 12. Center for Research in Molecular Medicine and Chronic Diseases (CIMUS)_ Singular Research Centers 2016. Xunta de Galicia. Consellería de Educación e Ordenación Universitaria. Ref.ED431G/05. 01/01/2016_30/11/2019. 2.482.289,47 €. 13. Consolidación e estruturación. REDES GI_1685 REGID: Galician Network for Research and Development of Medicines. Xunta de Galicia. Consellería de Cultura, Educación e Ordenación Universitaria. Reference: R2014/025. 24/06/2014_23/06/2016. 120.000,00 €. 14. Initial development of new curcumin derivatives with potential application in the treatment of neurodegenerative diseases. Consellería de Cultura, Educación e Ordenación Universitaria. Xunta de Galicia. Reference: EM2014/016. 14/05/2014_30/11/2016. 93.000,00 €. 15. Effect of tobacco and its components on the pathogenic, biochemical and molecular mechanisms of chronic pancreatitis: prevention of pancreatic cancer. Fundación Mutua Madrileña. Reference: MMA2010. 2010_2012 12.000,00 €. 16. Consolidation and structuring of the research units of the Galician R+D+i system. Investigation groups. Entidad financiadora: Consellería de Economía Programa xeral de consolidación e estruturación do sistema galego de I +D+i. Reference: 2010_PG430. 01/01/2010_17/12/2010. 16.724,00 €. 17. Consolidation and structuring of the research units of the Galician R+D+i system. Investigation groups. Xunta de Galicia. Consellería de Economía. Programa xeral de consolidación e estruturación do sistema galego de I +D+i. Reference: INCITE09E2R203045ES. 01/01/2009_11/12/2009. 23.892,00 €. 18. Study of the effects of resveratrol isomers on various physiological factors involved in cardiovascular diseases. Xunta de Galicia. Dirección Xeral de I+D. Reference: 08CSA019203PR. 31/10/2008_31/10/2011. 46.352,07 €. 19. Fibrin: Producción de ingredientes alimentarios funcionales a partir de produtos tradicionais do medio rural galego. Fase I: investigación industrial. Tecnomiza S.L.01/10/2008_30/09/2009. 23.625,00 €. 20. Raisin d'or: producción de vino desalcoholizado enriquecido en polifenoles con efectos beneficiosos sobre la salud humana. Fase I. Investigación industrial. Tecnomiza I+D S.L.16/01/2008_30/09/2010. 69.000 €. 21. Consolidation and structuring of competitive research units (GI_1683). Xunta de Galicia. Consellería de Innovación e Industria. Reference: INCITE08E1R203054ES. 01/01/2008_21/11/2008. 17.066,00 €. 22. Grants for the consolidation of the research units of the Galician research and innovation system: Research Group GI_1683. Xunta de Galicia. Consellería de Innovación e Industria. INCITE07PXI203039ES. 21/12/2007_20/12/2008. 24.379,00 €. 23. Study of the cardioprotective effects of polyphenols analogues of resveratrol and flavonoids. Fondo de Investigaciones Sanitarias

(FIS), Ministerio de Sanidad y Consumo. Reference: PI061537. 31/12/2006_30/12/2009. 55.297,00 €. 24. Synthesis and study of the cardiovascular and antithrombotic effects of various derivatives of resveratrol (II). Xunta de Galicia. Consellería de Innovación, Industria e Comercio. PGIDT_2002 Biotecnoloxía, Farmacia e Saúde. Reference: PGIDIT05BTF20302PR_1. 05/08/2005_31/10/2008. 100.100,00 €. 25. Synthesis and study of the cardiovascular and antithrombotic effects of various derivatives of resveratrol (I). Xunta de Galicia. Consellería de Innovación, Industria e Comercio. PGIDT_2002 Biotecnoloxía, Farmacia e Saúde. Reference: PGIDIT02BTF20301PR. 15/10/2002_14/10/2005. 68.200,00 €. 26. Study of the cardiovascular effects of trans_resveratrol and epigallocatechin gallate in rats. Xunta de Galicia. PGIDT _ PXI (Programa Xeral de Investigación). Reference: 27. PGIDIT02PXIC20305PN. 14/08/2002_13/08/2003. 13.200,00 €. 28. Two distinct, regulated exocytotic pathways in rat pancreatic acinar cells. Biotechnology and Biological Sciences Research Council (BBSRC), United Kingdom. Reference: C111044 1999_2001. 194.538£ (~229.382 €). 29. A study of the possible effects of polyphenolic flavonoids on calcium signalling and nitric oxide production in the vascular endothelium. Institut de Produits de Synthèse et d'Extraction Naturelle (IPSEN), Francia. 1997_1999. 30. Pharmacological study as potential antihypertensive agents of various flavones extracted from *Centaurea corcubionensis*. Xunta de Galicia. Consellería de Educación e Ordenación Universitaria, CICETGA. Reference: XUGA20312B97. 22/07/1997_22/07/2000. 66.652,23 €. 31. Pharmacological study as potential antihypertensive agents of various alkaloids extracted from *Glaucium flavum*. Gobierno de España. Comisión Interministerial de Ciencia y Tecnología (CICYT). Reference: SAF94_0440. 20/05/1994_19/05/1997. 48.080,96 €. 32. New antihypertensive drugs: pharmacological study of various alkaloids of natural origin extracted from *Platycapnos spicata*. Xunta de Galicia. Consellería de Educación e Ordenación Universitaria, CICETGA. Reference: XUGA20306B93. 07/04/1994_07/04/1996. 21.035,42 €. 33. Pharmacological study as potential antihypertensive agents of glaucine derivatives of natural and synthetic origin. Gobierno de España. Comisión Interministerial de Ciencia y Tecnología (CICYT). Plan Nacional de I+D. Programa Nacional de Salud y Farmacia. Reference: SAF92_0585. 20/07/1992_19/07/1994. 45.676,91 €. 34. Influence of atheromatosis on the reactivity of the rat aorta. Effects of different modulators of calcium channels on the evolution of the process. Xunta de Galicia Consellería de Educación e Ordenación Universitaria, CICETGA. Reference: XUGA20312B90. 26/03/1991_26/03/1993. 28.247,56 €.

Memberships

Other Relevant Information